Entecavir

Generic Name: Entecavir

Brand Names: Baraclude, Entecavir Viatris (previously Entecavir Mylan), Entecavir Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₅N_₅O_₃

CAS Number: 142217-69-4

Unique Ingredient Identifier: NNU2O4609D

Background: Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS).
...

Indication: For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Associated Conditions: Chronic Hepatitis B Infection

Associated Therapies: -

Clinical Trials

Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT

Phase 4

Conditions: Chronic Hepatitis

Interventions: Drug: placebo
Drug: Entecavir

First Posted Date: 2013-04-17

Last Posted Date: 2013-04-17

Lead Sponsor: National Cheng-Kung University Hospital

Target Recruit Count: 130

Registration Number: NCT01833611

Locations: 🇨🇳
Chia-Yi Christian Hospital, Chia-Yi, Taiwan
🇨🇳
Chang-Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

and more 1 locations

Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

Conditions: Liver Cirrhosis
Hepatitis B

Interventions: Drug: Lamivudine plus Adefovir Dipivoxil
Drug: Entecavir

First Posted Date: 2012-11-02

Last Posted Date: 2015-07-28

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 621

Registration Number: NCT01720238

Locations: 🇨🇳
Beijing 302 Hospital, Beijing, Beijing, China
🇨🇳
Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳
PeKing University People's Hopital, Beijing, Beijing, China

and more 5 locations

Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment

Terminated

Conditions: Hepatitis B

Interventions: Drug: Tenofovir Disoproxil Fumarate
Drug: Entecavir

First Posted Date: 2012-10-29

Last Posted Date: 2017-09-06

Lead Sponsor: New Discovery LLC

Target Recruit Count: 48

Registration Number: NCT01715987

Locations: 🇺🇸
New Discovery LLC, New York, New York, United States
🇺🇸
Asian Pacific Liver Center at St. Vincent Medical Center, Los Angeles, California, United States

Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: entecavir
Drug: tenofovir

First Posted Date: 2012-10-22

Last Posted Date: 2016-11-09

Lead Sponsor: Korea University

Target Recruit Count: 60

Registration Number: NCT01711567

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of

Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα

Phase 3

Terminated

Conditions: Chronic Hepatitis B
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis

Interventions: Drug: Placebo
Drug: Entecavir

First Posted Date: 2012-09-27

Last Posted Date: 2017-03-06

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 43

Registration Number: NCT01694264

Locations: 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of

and more 19 locations

Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B

Phase 4

Completed

Conditions: Chronic Viral Hepatitis B Without Delta-agent

Interventions: Drug: Tenofovir
Drug: Entecavir

First Posted Date: 2012-07-12

Last Posted Date: 2018-05-09

Lead Sponsor: Asan Medical Center

Target Recruit Count: 88

Registration Number: NCT01639092

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B

Phase 4

Completed

Conditions: Chronic Viral Hepatitis B Without Delta-agent

Interventions: Drug: Tenofovir
Drug: Entecavir

First Posted Date: 2012-07-12

Last Posted Date: 2018-02-20

Lead Sponsor: Asan Medical Center

Target Recruit Count: 102

Registration Number: NCT01639066

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

Phase 4

Terminated

Conditions: Chronic Hepatitis B

Interventions: Drug: Lamivudine
Drug: Entecavir

First Posted Date: 2012-06-25

Last Posted Date: 2016-10-18

Lead Sponsor: Taichung Veterans General Hospital

Target Recruit Count: 17

Registration Number: NCT01627223

Locations: 🇨🇳
ChengChing Hospital, Taichung, Taiwan
🇨🇳
Chung Shan Medical University Hospital, Taichung, Taiwan
🇨🇳
National Taiwan University Hospital Yu-Lin Branch, YuLin, Taiwan

and more 5 locations

Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss

Not Applicable

Conditions: Hepatitis B

Interventions: Drug: Entecavir
Drug: Peginterferon alfa-2a

First Posted Date: 2012-05-15

Last Posted Date: 2012-05-15

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 60

Registration Number: NCT01599130

Locations: 🇨🇳
The Third Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

Phase 3

Completed

Conditions: Chronic Viral Hepatitis B Without Delta-agent

Interventions: Drug: Entecavir
Drug: Telbivudine

First Posted Date: 2012-05-10

Last Posted Date: 2017-01-26

Lead Sponsor: Asan Medical Center

Target Recruit Count: 98

Registration Number: NCT01595685

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy